Merck & Co. won regulatory approval for a pill version of powerful cholesterol medication that Wall Street analysts have said could generate billions of annual sales. https://t.co/yA1QYfuZeD ...

What exactly is Lilly buying with this thing, Madison. So Lilly is buying into this fast growing psychedelic space, which was once really on the fringes of drug development, but has gotten a lot more interesting and a lot more interest from drug makers over the last year or so. There are now a couple of companies that are nearing potentially FDA approval.They're in late stages of testing. AtaiBeckley is moving into late stages of testing. They have their lead drug is called BPL zero zero three.It's actually ...

Lily says that it is acquiring psychedelic drug developer Tai Beckley. And Lily will pay $675 in cash or $2.8% billion upfront and another1 billion if certain developmental and regulatory milestones are met. And so a Tai Beckley, their lead drug is related to the psychedelic drug DMT.And the company's testing it for treatment resistant depression. And it's a nasal spray that's a little bit like um J&J's drug spado. So it's administered in a clinic and then patients are monitored for a couple hours and again ...

Merck said the U.S. FDA has approved its cholesterol pill, the first of its kind to receive the health regulator’s ​nod, bolstering the drugmaker’s efforts to diversify beyond its blockbuster ‌cancer treatment Keytruda. https://t.co/N7MkOWpCfm https://t.co/CQwauU53AY ...

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker’s recent buying spree. https://t.co/C6X2UJZnOo ...

You were just on a panel and you said you have an aversion to making news. I'm going to try. Nonetheless, I think there are a lot of folks wondering about Brazil in particular.As soon as this test case for the section 301 tariffs statutory deadline is today. Anything that you can say about the process and where it stands and what we can expect, it's today. So our section 301 investigations, they are legal investigations.We have two sets of hearings. We do two sets of public comments. And we're focused on un ...

The world’s largest drugmaker is betting big on preventive medicines—and learning from big tech https://t.co/BhrrA44rzT ...